ArticleWorld journal of surgical oncology2025
Establishing high risk factors for recurrence in stage I/II colorectal cancer: a metropolitan perspective.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic value of lncRNA DARS-AS1 in colorectal cancer and its regulatory effect on tumor progression.BMC gastroenterology · 2026Article
- Tumor mitochondrial respiration rather than glycolytic activity predicts recurrence in colorectal cancer: an ex vivo bioenergetic profiling study.BMC gastroenterology · 2026Article
- Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort.Molecular medicine (Cambridge, Mass.) · 2026Article
- A machine learning-based transcriptomic signature for predicting tumor recurrence after curative resection in T1 colorectal cancer: a retrospective multicenter cohort study (The Tw1CE trial).International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) carries a significant disease burden worldwide. With the implementation of screening programs for colorectal cancer, the incidence of early-stage disease is increasing. As such, it is imperative to revise and optimise our risk stratification and treatment pathways for this patient cohort.
methodsThis retrospective cohort study analyses clinicopathological features of early colorectal cancer from our institutional database between 2010 and 2020. Univariate and multivariable analyses were used to identify clinical and disease factors that may be associated with disease recurrence.
results195 patients with stage one and two colorectal cancers were identified. Twenty-six patients experienced recurrence overall (13.3%). Recurrence rates were 8.4% and 17% in stage I and II disease, respectively. 19.2% of patients with recurrence did not possess any of the six commonly recognised risk factors. 5-year mortality rate for those patients who experienced recurrence was 61.5%. Using a multivariable model, venous invasion (p = 0.02), synchronous cancers (p = 0.017), microsatellite stability (p = 0.018) and peri-operative blood transfusion (p = 0.01) were found to be risk factors for recurrence.
conclusionEarly colorectal cancers carry a significant risk of recurrence and associated disease burden. Currently identified risk factors may not provide the full picture in terms of prognostic impact. Optimisation of risk stratification will assist to guide adjuvant therapy in this group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.